newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

  • Jade Biosciences announced the first participant has been dosed in the first-in-human Phase 1 clinical trial of JADE201.
  • JADE201 is an investigational, half-life extended, afucosylated monoclonal antibody targeting BAFF-R designed to deplete B cells via enhanced effector function & BAFF signal blockade.
  • Preclinical data demonstrated dose-dependent BAFF-R occupancy, extended half-life, & sustained B cell depletion in non-human primates.
  • Interim Phase 1 data in rheumatoid arthritis are expected in 2027 to inform indication prioritization across multiple potential autoimmune indications.
  • The trial is a randomized, placebo-controlled study evaluating single ascending doses of JADE201 in participants with rheumatoid arthritis to assess safety, tolerability, pharmacokinetics, & pharmacodynamics.
  • Jade Biosciences is a clinical-stage company focused on autoimmune therapies, with JADE101 targeting APRIL for IgA nephropathy & JADE301 as an undisclosed candidate.
  • The company launched based on assets licensed from Paragon Therapeutics.